Drug Profile
GSK 159802
Alternative Names: 159802; GSK159802Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Theravance
- Developer GSK
- Class Antiasthmatics
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 06 Jul 2007 GSK 159802 is still in active development
- 06 Dec 2005 Phase-IIa clinical trials in Asthma (Inhalation)
- 06 Dec 2005 Phase-IIa clinical trials in Chronic obstructive pulmonary disease (Inhalation)